Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment
A pilot study
Yang Ni (MD, PhD)a, Jingwang Bi (MD)b, Xin Ye (MD)a, Weijun Fan (MD)c, Guohua Yu (MD)d, Xia Yang (MD, PhD)a, Guanghui Huang (MD)a, Wenhong Li (MD)a, Jiao Wang (MD)a, Xiaoying Han (MD)a, Xiang Ni (MD)a, Zhigang Wei (MD, PhD)a, Mingyong Han (MD, PhD)a, Aimin Zheng (MD, PhD)a, Xia Yang (MD, PhD)a, Guoliang Xue (MD)b, Wenhong Li (MD)a, Jiao Wang (MD)a, Xiang Ni (MD)a, Zhigang Wei (MD, PhD)a, Mingyong Han (MD, PhD)a, Aimin Zheng (MD, PhD)a, Guohua Yu (MD)d, Xia Yang (MD, PhD)a, Guoliang Xue (MD)b, Weijun Fan (MD)c, Chao Wan (MD)c

Abstract
The non-small cell lung cancer (NSCLC) patients that experienced good clinical response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKis) will ultimately develop acquired resistance. This retrospective study was performed to explore the potential survival benefit of microwave ablation (MWA) therapy in epidermal growth factor receptor (EGFR)-mutant NSCLC that developed extra-central nervous system (CNS) oligoprogressive disease during TKI treatment.

We retrospectively analyzed 54 NSCLC patients with EGFR mutations who showed a clinical benefit from initial EGFR-TKI therapy and developed extra-CNS oligoprogressive disease at our institutions. Twenty eight patients received MWA as a local therapy for the metastatic sites and continued on the same TKIs (MWA group). The following 26 patients received systemic chemotherapy after progression (chemotherapy group). The progression-free survival (PFS1) was calculated from initiation of targeted therapy to first progression. Progression-free survival (PFS2) was defined from first progression to second progression after MWA or chemotherapy. Overall survival (OS) was calculated from the time of diagnosis to the date of last follow-up or death.

The median PFS1 for both groups was similar (median 12.6 vs. 12.9 months, HR 0.63). However, the MWA group patients had a significantly longer PFS2 (median 8.8 vs. 5.8 months, hazards ratio [HR] 0.357) and better OS (median 27.7 vs. 20.0, HR 0.238) in comparison with chemotherapy group. Multivariate analysis and the internal validation identified MWA as the main favorable prognostic factor for PFS2 and OS. In the MWA group, the median PFS2 for complete ablation was significantly longer than that for incomplete ablation (11 vs. 4.2 months, HR 0.29, P < 0.05).

MWA with continued EGFR inhibition might be associated with favorable progression-free survival (PFS) and OS in patients with extra-CNS oligometastatic disease. MWA as a local therapy for extra-CNS oligometastatic disease should be considered for NSCLC with acquired resistance to EGFR-TKis.

Abbreviations: BS = bone scintigraphy, CT = computed tomography, EGFR = epidermal growth factor receptor, MRI = magnetic resonance imaging, MWA = microwave ablation, NSCLC = non-small cell lung cancer, OS = overall survival, PET/CT = positron emission tomography/CT, PFS = progression-free survival, RECIST = response evaluation criteria in solid tumors, TKI = tyrosine kinase inhibitor.
1. Introduction

Activating epidermal growth factor receptor (EGFR) mutations occur in 10 to 20% of patients with non-small cell lung cancer (NSCLC) in North American and European populations and in up to 60% among Asians populations.\(^{[1]}\) Treatment of EGFR-mutant NSCLC with specific tyrosine kinase inhibitor (TKI) that target EGFR, such as gefitinib, erlotinib or afatinib, has led to remarkable tumor shrinkage and improvement in progression-free survival (PFS) and quality of life compared with standard chemotherapy.\(^{[2–4]}\) Based on the results of numerous studies, EGFR sensitizing mutant advanced NSCLC patients should receive first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) treatment.\(^{[3–7]}\)

Despite the initial advancement of these agents, most patients ultimately develop acquired resistance to such TKIs after 1 to 2 years.\(^{[3,4,8,9]}\) Several resistant mechanisms have been identified, such as T790M missense mutation, amplification of MET, activation of alternative pathways (IGF-1, HGF, PI3CA, AXL), and, in rare instances, transformation to small-cell histology.\(^{[10–16]}\) Although studies of second-generation, irreversible EGFR-TKIs and other novel agents are ongoing, there are no currently approved targeted therapies specific for treatment of such patients upon progression. Cytotoxic chemotherapy alone used to be the standard therapeutic option at the time of progression while continuation of TKI therapy by itself or in combination with chemotherapy seems to provide continued clinical benefit.\(^{[17–19]}\) It may be in accordance with the tumor heterogeneity in the development of resistance to targeted therapies and minor tumor cell populations will still be sensitive to the previous EGFR-TKIs.

Different patterns of progressive disease may represent different biological molecular mechanisms. So, it is important to distinguish among these patterns as different therapeutic strategies may apply. Considering the growth rate and number of growing tumour lesions, progressive disease during TKI treatment can be generally distinguished in 3 patterns: intracranial disease progression, development of 1 or few distant metastatic sites while the patient remains asymptomatic, and systemic and/or symptomatic disease progression.\(^{[20,21]}\) The first two fall into the general term of oligoprogressive disease. Typically, the definition of oligoprogressive disease refers to the presence of fewer than 5 discrete metastatic sites. Local therapy with continued EGFR inhibition has been shown to be effective for treating patients with oligoprogressive disease and associated with long PFS and OS.\(^{[22,23]}\) As a new thermal ablation method, microwave ablation (MWA) for NSCLC is likely to be increasingly used, given its theoretical advantages over radiofrequency ablation (RFA) including a less severe heat sink effect and faster, greater heating.\(^{[24]}\) We previously reported that advanced and medically inoperable stage I NSCLC could benefit from MWA therapy. Major complications as a result of MWA are rare and tolerable.\(^{[23–28]}\) Therefore, we performed the retrospective multicenter study to explore the potential benefit of MWA in treating EGFR acquired resistance NSCLC with extra-CNS oligoprogressive disease.

2. Materials and methods

2.1. Patients and eligibility

We conducted a retrospective multicenter study at Shandong Provincial Hospital Affiliated to Shandong University, Sun Yat-sen University Cancer Center, Jinan Military General Hospital of Chinese People’s Liberation Army and Weifang People’s Hospital Affiliated to Weifang Medical University between March 2010 and January 2016. Patients eligible for inclusion in this retrospective analysis included histologically or cytologically proven EGFR-mutant NSCLC treated with erlotinib or gefitinib, objective clinical benefit from erlotinib or gefitinib monotherapy, experienced progression of disease despite the maintenance of erlotinib or gefitinib. EGFR mutations (exon 19 deletions or exon 21 L858R mutations) were examined either through direct sequencing or allele-specific polymerase chain reaction assays. Objective clinical benefit of EGFR-TKIs was defined by either: complete or partial response (CR or PR), or durable stable disease (≥6 months) according to the criteria for acquired resistance proposed by Jackman et al.\(^{[9]}\) We collected initial baseline clinical characteristics including sex, age at diagnosis, smoking status, tumor histology, prior therapy, date of diagnosis of any known extra-CNS involvement and sites of metastatic disease of all enrolled patients by retrospective collection from electronic records.

This study was performed in accordance with the declaration of Helsinki and the ethical guidelines and regulations of China. The protocol was approved by the ethics committees of each center before the initiation of enrollment. Written informed consent was obtained from all patients before enrollment in the study.

2.2. Treatment and follow-up

All EGFR-mutant patients received erlotinib or gefitinib starting at 150 mg or 250 mg once a day. Patients received routine chest computed tomography (CT) every 1 to 2 months to assess the local response according to the response evaluation criteria in solid tumors.\(^{[29]}\) Additional procedures including CT, magnetic resonance imaging, bone scintigraphy and positron emission tomography/CT were applied to evaluate extrapulmonary symptoms and metastatic sites. All patients randomly received MWA or chemotherapy after progression on EGFR-TKIs. In the MWA group, once the acquired resistance was identified patients received MWA followed by the same targeted therapy. After 1 month of MWA, a new baseline for surveillance was established. At 1, 3, 6, 9, and 12 months after MWA, patients received CT scan to assess their response to treatment and to identify adverse events. The patients then underwent imaging every 3 months surveillance thereafter. Sites of first progression were documented. Patients in the chemotherapy group received 2 to 6 cycles of platinum-based systemic chemotherapy followed by the same EGFR-TKI after acquired resistance, and detailed chemotherapy regimens are listed in the Table S1, http://links.lww.com/MD/B67. Chemotherapy was paused until disease progression or unacceptable toxicity.
2.3. MWA procedure

Instrumentation: (1) MTC-3C microwave ablation system (Nanjing Qi Ya Research Institute of Microwave Electric, China. Registration standard: YZB/country1408–2003. No: SFDA (III) 20073251059) or (2) ECO-2450B microwave ablation system (Nanjing, ECO Microwave Institute, China. Registration standard: YZB/country1475–2013. No: SFDA (III) 20112251456) was used for MWA treatment. Generally, we set the microwave emission frequency at 2450±50 MHz and ablation power between 60 and 80 W. The effective length of the antenna is 100 to 180 mm and 14G to 20G outside diameter. In addition, a water circulation cooling system was applied to reduce the antenna surface temperature. For tumors in close proximity to major blood vessels, we used single or double antennae, respectively, to reduce the antenna surface temperature.

Stage at initial diagnosis

| Stage | MWA group (n=28) | Chemotherapy group (n=26) | χ²/t | P |
|-------|------------------|--------------------------|------|---|
| I     | 11 (39.3)        | 7 (26.9)                 | 0.927| 0.336|
| II    | 5 (17.9)         | 3 (11.5)                 | 0.123| 0.728|
| N     | 12 (42.9)        | 16 (61.5)                | 0.271| 0.610|

Site of metastatic disease at initial diagnosis

| Tumor type | MWA group (n=28) | Chemotherapy group (n=26) | χ²/t | P |
|------------|------------------|--------------------------|------|---|
| Lung       | 15 (53.6)        | 14 (53.8)                | 0.130| 0.720|
| Lymph node | 2 (7.1)          | 1 (3.8)                  | 0.714| 0.400|
| Adrenal gland | 4 (14.3)    | 3 (11.5)                 | 0.000| 1.000|
| Liver      | 5 (17.9)         | 2 (7.7)                  | 0.271| 0.610|
| Pleura     | 2 (7.1)          | 2 (7.7)                  | 0.000| 1.000|
| Bone       | 0 (0)            | 4 (15.5)                 | 0.000| 1.000|

EGFR = epidermal growth factor receptor, MWA = microwave ablation, TKI = tyrosine kinase inhibitor.

2.4. Statistical analysis

Pearson’s Chi-square (or Fisher’s exact) and t-test were used to determine differences between groups. Median progression-free survival (PFS1) was calculated from time of initiation of targeted therapy to first progression of disease or clinical progression (as assessed by clinician). PFS2 was defined from the time of first progression to second progression after MWA or chemotherapy. OS was calculated from the time of diagnosis to the date of last follow-up or death from any cause. Survival curves were estimated using Kaplan–Meier method. Patients who did not experience progression or death during the study time were censored at the time of the last available follow-up. Univariable and multivariable Cox proportional hazards regression models were used to assess the association between each of the variables and PFS2 or OS. For the multivariable analysis model, we include treatment strategy variable, which was statistically significant on univariable analysis.

We used bootstrapping for bias correction (n=1000 bootstrap samples). Random samples (sample size was equivalent to original cohort) were drawn from the original data set with replacement. Then, we applied the same Cox model, which was derived from the original cohort to the bootstrap samples. One thousand bootstrapping-based model performance indices were independently generated by repeating this process 1000 times. The mean value of the 1000 performance indices is the bias-corrected estimate, which is considered to estimate the nomogram performance that could be expected in a separate but similar patient population. The average and standard deviation of these 1000 bootstrap samples of the regression parameter were calculated as the bootstrap estimate and standard error (SE) of the parameter. Statistical analysis was performed using SPSS for Windows Version 17.0 (IBM, Chicago, IL) and R software version 3.1.1 (The R Foundation for Statistical Computing). All analyses were two sided with a P-value <0.05 considered statistically significant.

3. Results

3.1. Patients characteristics

From Jan 2010 to Jan 2016, 54 patients were enrolled in this study. Twenty-eight patients received MWA while 26 patients received chemotherapy after acquired resistance to TKIs. The characteristics of all patients are shown in Table 1. EGFR mutations were confirmed in all patients, with exon 19 deletion mutation being most common (50% in MWA group, 46.2% in chemotherapy group), followed by exon 21 L858R mutation (39.3% in MWA group, 38.5% in chemotherapy group) and other type of mutation (10.7% in MWA group, 15.3% in chemotherapy group). All patients had oligoprogressive disease.
(<5 sites of disease) at the time of PFS1 and the pattern of progression for these patients is also summarized in Table 1. There was no significant difference in age, sex, smoking history, stage at diagnosis, best response to TKI, and sites of metastatic disease between the MWA group and chemotherapy group.

3.2. Treatment procedures and complications after MWA

All patients with extra-CNS oligoprogressive disease received MWA followed by continuation of targeted therapy in the present study. The median time from the first progression to MWA was 3 weeks. Thirty-one metastatic sites in 28 cases were ablated. The mean size of the metastatic sites was 3.1 cm (range, 1–6.4 cm). Most MWAs were well tolerated. No patient died during the procedure or within 30 days after MWA. Pain was the common side effect and 10 patients (35.7%) suffered moderate pain after MWA, but no severe post-ablation pain occurred. Post-ablation syndrome including fever (under 38.5°C), fatigue, general malaise, nausea, and vomiting, etc. occurred in 9 patients. Postoperative pneumothorax was observed in 10 patients (35.7%), in which 2 of them received chest tube drainage. Five patients (17.8%) had pleural effusion (of which 1 case underwent chest tube insertion) after the MWA. Hemoptysis occurred in 2 cases (7.1%) and the conventional application of hemostatic agents including snake venom thrombin, glucocorticoids, could effectively stop bleeding. The average length of hospital stay was 4.3 days (3–17 days).

3.3. Outcomes

The median follow-up for this study was 23.5 months (range, 7–70 months). Among the 28 patients in the MWA group, 11 of them progressed after MWA during the study period, and 7 patients died. While 21 of 26 patients in the chemotherapy group died. The difference of PFS1 in both groups was not significant (12.6 months vs. 12.9 months, HR 0.63, CI 0.350–1.142, P = 0.13) (Fig. 1A). However, the patients in MWA group had a significantly longer PFS2 than those in chemotherapy group (8.8 months vs. 5.8 months, HR 0.357, CI 0.169–0.751, P = 0.007) (Figs. 1B and 2). In addition, the OS in MWA group was also longer than that in chemotherapy group (27.7 months vs. 20.0 months, HR 0.238, CI 0.112–0.505, P = 0.0002) (Fig. 1C).

The variables listed in Table 1 were examined (Cox Regression) for their association with PFS2 and OS. Results of the univariate analyses are shown in Table 2. Treatment strategy with univariate significance (P < 0.05) was selected for the multivariate analysis, and the detailed results and the hazard ratios of the multivariate analysis estimated by Cox regression are listed in Table 2. We confirmed the results of the multivariate analysis by using the bootstrap resampling technique mentioned above. We observed the closeness of the bootstrap estimates to those obtained in the final Cox model, which validated the final results (Table 3).

In the MWA group, the overall complete ablation rate achieved 78.6% (22 of 26). The median PFS2 for complete ablation was significantly longer than that for incomplete ablation (11 vs. 4.2 months, hazard ratio: 0.2874, 95% CI of the ratio: 0.062–1.339, P < 0.05). The difference of OS between the two groups was not significant (39 vs. 26.4, P > 0.05) (Fig. 3).
Table 2

Results of Cox regression analyses.

| Variables                        | PFS2                      | OS                        | Reference category |
|---------------------------------|---------------------------|---------------------------|--------------------|
|                                 | B | SE | HR | 95% CI | P    | B | SE | HR | 95% CI | P    |
| Gender                          |   |    |    |        |      |    |    |    |        |      |
| Age                             | 0.181 | 0.630 | 1.198 | 0.348–4.121 | 0.774 | 0.248 | 0.579 | 1.282 | 0.413–3.985 | 0.668 |
| Smoking history                 | 0.010 | 0.025 | 1.010 | 0.901–1.061 | 0.695 | 0.044 | 0.024 | 1.045 | 0.998–1.095 | 0.682 |
| Stage at initial diagnosis      | 1.322 | 0.854 | 3.789 | 0.711–20.210 | 0.110 | 1.064 | 0.910 | 2.890 | 0.488–17.237 | 0.242 |
| EGFR mutation type              | 0.046 | 0.464 | 1.047 | 0.421–2.600 | 0.921 | 0.502 | 0.478 | 1.652 | 0.647–4.218 | 0.294 |
| Best response to TKI            | 1.559 | 1.436 | 4.755 | 0.285–79.272 | 0.277 | 1.123 | 0.915 | 3.075 | 0.511–18.495 | 0.220 |
| Site of metastatic disease      | 0.468 | 0.973 | 0.944 | 0.316–1.869 | 0.562 | 0.887 | 0.398 | 0.687 | 0.074–4.600 | 0.563 |
| Treatment                       | 0.263 | 0.453 | 0.769 | 0.316–1.869 | 0.562 | 0.263 | 0.453 | 0.769 | 0.316–1.869 | 0.562 |

Multivariable Cox regression analysis for PFS2 and OS

| Variables                        | PFS2                      | OS                        | Reference category |
|---------------------------------|---------------------------|---------------------------|--------------------|
|                                 | B | SE | HR | 95% CI | P    | B | SE | HR | 95% CI | P    |
| Treatment                       | −1.128 | 0.449 | 0.324 | 0.134–0.781 | 0.012 | −1.612 | 0.448 | 0.200 | 0.083–0.480 | <0.001 |

4. Discussion

The past decade witnessed the dramatic alteration in the treatment of NSCLC with the identification of somatic gene mutations that underlie tumor initiation and maintenance. EGFR mutations were first identified in lung cancer after clinical benefit to EGFR tyrosine kinase inhibitors was observed. First-line TKI therapy is recommended in NSCLC harboring an EGFR mutation. Unfortunately, most patients who initially benefit from erlotinib or gefitinib ultimately developed acquired resistance to these drugs, and there are limited options for these patients. Patients treated with erlotinib or gefitinib monotherapy in this study had a median PFS1 of 12.6 months, which is similar to that of chemotherapy group (12.9 months) and consistent with literature precedent, especially with the data of East Asian patients, indicating that we do not seem to have preselected a more indolent population for MWA within this study.

Cytotoxic chemotherapy or participation in a clinical trial was considered as the standard treatment in this setting. EGFR-TKI was replaced with docetaxel or pemetrexed but efficacies of these agents were not satisfactory. The median PFS2 of pemetrexed and docetaxel was 3.9 months and 4.1 months, respectively.[32,33] Pemetrexed in combination with erlotinib or gefitinib after disease progression showed better response and was associated with a median PFS2 of 7.0 months.[19] Recent data suggest that for patients with EGFR-mutation who develop highly localized disease progression (oligoprogressive disease), local therapy to these sites with surgery or radiation, in combination with ongoing use of the same TKI, might also be clinically beneficial. It was recently reported that Oncogene-addicted NSCLC with CNS and/or extra-CNS oligoprogressive disease on relevant targeted therapies is suitable for local ablative therapy and continuation of the targeted agents, and is associated with more than 6 months of additional disease control.[22] Moreover, Yu et al.[23] reported EGFR-mutant lung cancers with acquired resistance to EGFR-TKI therapy are amenable to local therapy including surgery or radiation followed by continued targeted therapy, and 10 months additional disease control was observed. However, there is little published data about the use of MWA for oligoprogressive disease.

Table 3

Summary of variables for 1000 bootstrap samples.

| Variables | B | Bias | SE |
|-----------|---|------|----|
| PFS2      | −1.0239 | 1.026 | 0.429 |
| OS        | −1.689 | 1.402 | 0.460 |

OS = overall survival, SE = standard error.
disease on therapy. This is the first study to evaluate the efficacy and safety of MWA as a local therapy for patients with TKI acquired resistance. In this study, the MWA group had a similar PFS1 with that of chemotherapy group (control group). However, the PFS2 and OS were significantly longer in patients of MWA group compared with chemotherapy group. Our data suggest that MWA in combination with continuation of the TKIs may be associated with longer PFS and OS in patients with EGFR-mutation on targeted therapy who developed less than two systemic progressive lesions. These results expand on the role of local therapy in EGFR-mutant NSCLC that developed extra-CNS oligoprogressive disease during TKI treatment and suggest that these patients may benefit from the MWA.

The mechanism of acquired resistance to EGFR-TKIs in NSCLC is still not well understood. Several molecular mechanisms have been elucidated and generally can be classified into 3 main categories: alterations in EGFR itself, activation of bypass signaling pathways, and phenotypic transformation. The most frequent mechanism of acquired resistance to EGFR-TKIs is the secondary T790M mutation in EGFR which is identified in approximately 50 to 60% of patients. However, in metastatic cancers, biological heterogeneity among tumour cells pre-exists at the time of clinical presentation and tumors resistant to EGFR-TKIs may be composed of a heterogeneous mix of TKI-sensitive and TKI-resistant cells. Continuation of targeted therapy can lead to ongoing benefit in nonprogressing clones, which have not developed acquired resistance. Our data indicated that the efficacy of MWA together with continuation of TKIs may be superior to TKIs treatment alone, suggesting local microwave ablative therapy of the resistant clone before widespread dissemination is associated with prolonged disease control.

In the present study, the most common complication for MWA therapy was pneumothorax, followed by pleural effusion and hemothorax. Complications can be controlled by proper treatments and there is no patient died during or within 30 days after the procedure. Therefore, MWA is a safe and well tolerable strategy for NSCLC patients.

Certainly, our study does have some limitations. The main limitation of this study lies in its retrospective nature and relatively small number of treated patients. Further limitations include the absence of pathological proof in metastatic disease and identification of the acquired resistance molecular characteristics. Prospective multicenter evaluation of MWA with large sample size is needed to define more clearly the effectiveness and safety of this treatment strategy.

Despite of these limitations, our results show that MWA with continued EGFR inhibition may extend disease control by over 8 months in patients with oligoprogressive disease. MWA as a local therapy for oligoprogressive disease should be considered for NSCLC with acquired resistance to EGFR-TKIs.

References

[1] Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339–46.
[2] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947–57.
[3] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUR-TAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
[4] Sequist LV, Yang JC, Yamamoto N, et al. Phase II study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:322–30.
[5] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
[6] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTG34505): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
[7] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42.
[8] Paz-Ares L, Soulieres D, Mezlekine I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14:51–69.
[9] Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:337–60.
[10] Engelmann JA, Zeijnalluha K, Mitsuodomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43.
[11] Reck J, Brennan C, Shiha JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932–7.
[12] Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494–501.
[13] Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:3764–9.
[14] Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852–60.
[15] Sequist LV, Wallman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
[16] Nwuruwyia F, Takahashi F, Murakami A, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012;44:151–6.
[17] Chmieliecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ta3.
[18] Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2013;19:17298–303.
[19] Yoshimura N, Okishio K, Mitsuoka S, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013;8:96–101.
[20] Kaifer JL, Smit EF. Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors. Oncology 2014;87:83–94.
[21] Matkas A, Mistrion D, Georgoulas V, et al. Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR-TKIs. Clin Lung Cancer 2015;16:252–61.
[22] Weischedrht A, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807–14.
[23] Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346–51.
[24] Ridge CA, Solomon SB, Thornton RH. Thermal ablation of stage I non-small cell lung carcinoma. Semin Intervent Radiol 2014;31:118–24.
[25] Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol 2015;38:135–42.
[26] Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol 2014;110:758–63.
[27] Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol 2015;32:464.

[28] Zheng A, Wang X, Yang X, et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg 2014;98:243–8.

[29] Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010;116:1336–43.

[30] Crocetti L, Bozzi E, Faviana P, et al. Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol 2010;33:818–27.

[31] Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595–605.

[32] Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 2011;72:333–9.

[33] Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744–52.

[34] Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11:473–81.